Shots:

• Shionogi to acquire Tetra for a total value of up to $500M which includes regulatory and commercial milestones- based on certain achievements. Following the acquisition- Shionogi will get global rights to Tetra’s portfolio for CNS disorders including BPN14770
• In 2018- the two companies collaborated and in 2020 expand their alliance to develop and commercialize BPN14770 for AD- FXS- and other indications. Additionally- Tetra is evaluating BPN14770 in a P-II study for FXS and has completed a P-II study for AD in the US
• BPN14770 is a selective inhibitor of phosphodiesterase-4D- having a potential to improve cognitive and memory function in CNS disorders and has received the US FDA’s ODD for FXS

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: StraitTimes

Related News: Tetra Therapeutics and Shionogi Expand their Existing 2018 Collaboration to Develop and Commercialize BPN14770